



14 June 2017
EMA/648897/2017

Agenda – Registries Initiative – Cystic Fibrosis Workshop

14 June 2017, 08:30 to 16:30 UK time

Welcome room: 3-M

Group-work will take place in rooms: 3-M, 3-H, 3-J, 3-K

Co-Chairs: Peter Mol and Xavier Kurz

Main Objectives of the Workshop:

- ❖ To agree on implementable recommendations on core data elements to be collected, consents, governance, quality assurance and registry interoperability.
- ❖ To agree a workplan for the further development and finalisation of recommendations to be used by registry holders and MAHs/MAAs.

| Item | Topics for information | Presenter | Time |
|-----------------------------|--|-------------------------------|----------------|
| 1. | Welcome | Peter Mol | 08:30-08:35h |
| 2. | Introduction: expected outcomes from the workshop | Xavier Kurz | 08:35-08:45h |
| 3. | Update on the Patient Registries Initiative | Patricia McGettigan | 08:45-09:00h |
| 4. | Future potential for registries in regulatory processes | Irmgard Eichler | 09:00 – 09:10h |
| 4. | Value and potential of patient registries in Cystic Fibrosis | Ed McKone | 09:10-09:40h |
| 5. | Plan for the day and explanation of the Group-work activities | Patricia McGettigan | 09:30-09:45 |
| Break - Coffee / tea | | | 09:45-10.00h |
| | Group-work Facilitator: Patricia McGettigan | Moderators | 10:00-12:00h |
| 6. | <i>Moderators outline how the groups will operate</i> <ul style="list-style-type: none">• Group 1: Common data elements that are needed by all stakeholders irrespective of the clinical/ academic/ regulatory/ reimbursement purposes of | Alison Cave / Kelly Plueschke | |



| Item | Topics for information | Presenter | Time |
|-----------------------------|--|--|--------------|
| | registries <ul style="list-style-type: none"> • Group 2: Informed consents and governance, data protection • Group 3: Common procedures and registry interoperability, quality assurance measures to support regulatory medicines evaluation | Xavier Kurz / Mireia Castillon Peter Mol / Carla Olmo Alonso | |
| Lunch | | | 12:00-13:00h |
| 7. | Agreement on Recommendations <ul style="list-style-type: none"> • Group 1: Common data elements needed by all stakeholders irrespective of the clinical/ academic/ regulatory/ reimbursement purposes of registries • Group 2: Informed consents, governance, data protection • Group 3: Common procedures and registry interoperability, quality assurance measures to support regulatory medicines evaluation | Alison Cave / Kelly Plueschke Xavier Kurz / Mireia Castillon Peter Mol / Carla Olmo Alonso | 13:00-14:00h |
| 8. | Each group prepares a summary of its Recommendations. Slides / Posters with the main points to be compiled for discussion all the Workshop participants | All | 14.00–14.30h |
| Break – Coffee / Tea | | | 14:30-14:45h |
| Item | Group Recommendations and Discussions | | |
| 9. | Presentation of Group 1, 2 and 3 Recommendations to all the participants Discussion / Agreement on Recommendations | Nominee from each Group | 14:45-16:00h |
| 10. | Conclusions and Next Steps | Peter Mol & Xavier Kurz | 16:00-16:30h |

- **Group 1:** Common data elements
 - **Expected outcomes:** Agreement on key common data elements needed by all stakeholders to fulfil their output needs
- **Group 2:** Consents and Governance
 - **Expected outcomes:** Outline agreement on consents and on a pragmatic and lean governance model adjusted for CF stakeholders' purposes and taking account of data protection requirements
- **Group 3:** Outline protocols for longitudinal data collection, registry interoperability, data verification and quality assurance for EMA qualification of CF Registries
 - **Expected outcomes:** Agreement on protocols for data collection (to facilitate registry interoperability) and on measures for data verification that would support quality assurance for EMA qualification.

Work Groups - Participants

| GROUP 1 - ROOM 3/M | Common data elements needed by all stakeholders; data validation |
|---------------------------------|--|
| Name | Background |
| Concepcion Prieto Yerro (AEMPS) | Regulators |
| Piotr Fiedor (Polish Agency) | Regulators |
| Hanneke van der Woude (CBG-MEB) | Regulators |
| Maria Fernandez (AEMPS) | Regulators |
| Gerhild Angyalosi (Novartis) | Industry |
| Claudia Meyer (Horizon Pharma) | Industry |
| Lutz Nährlich | Registries Holders |
| Laura Fregonese | EMA |
| Irmgard Eichler | EMA |
| Valerie Joynson (MHRA) | Regulators |
| Siobhán Carr | Registries Holders |
| Isabelle de Monestrol | Registries Holders |
| Peter Mol- Moderator | Regulators |
| Carla Alonso- Moderator | EMA |

| GROUP 2 - ROOM 3/M | Informed consents, governance, data protection |
|--|--|
| Name | Background |
| Ed McKone | Registries Holders |
| Melinda Sobor (OGYEI) | Regulators |
| Almath Spooner (HPRA) | Regulators |
| Sabine Straus (CBG-MEB) | Regulators |
| Flaminia Macchia (Vertex) | Industry |
| Anne-Ruth van Troostenburg de Bruyn (Gilead Science) | Industry |
| Carla Jonker (CBG-MEB) | Regulators |
| Frank Petavy | EMA |
| Martin Erik Nyeland (DKMA) | Regulators |
| Natividad Galiana (AEMPS) | Regulators |
| Hanne Vebert Olesen | Registries Holders |
| Jacquelin Noordhoek | Registries Holders |
| Xavier Kurz- Moderator | EMA |
| Mireia Castillon- Moderator | EMA |

| | |
|-----------------------------------|--|
| GROUP 3 - ROOM 3/K | Common procedures and registry interoperability, quality assurance measures to support regulatory medicines evaluation |
| Name | Background |
| Francois Meyer (HAS-SANTE) | HTA |
| Vincent Gulmans | Registries Holders |
| Lydie Lemonnier | Registries Holders |
| Robert Hemmings (MHRA) | Regulators (DNA) |
| Karolina Torneke (MPA) | Regulators |
| Nithyanandan Nagercoil (MHRA) | Regulators |
| Nils Kinnman (Vertex) | Industry |
| Saskia Dekker (Horizon Pharma) | Industry |
| Noreen Caine | Registries Holders |
| Andrea Taft (EMA) | Regulators |
| Jane Moseley (EMA) | EMA |
| Florian Gutzwiller (Novartis) | Industry |
| Alison Cave- Moderator | EMA |
| Kelly Plueschke- Moderator | EMA |

Group oversight: Patricia McGettigan, EMA

List of participants

Cystic Fibrosis Workshop

14 June 2017, 08.30-16.30, Room 3/M

| Presenter / Moderator / Rapporteur | Affiliation |
|------------------------------------|--|
| Peter Mol | Medicines Evaluation Board (The Netherlands) |
| Xavier Kurz | European Medicines Agency |
| Patricia McGettigan | European Medicines Agency |
| Ed McKone | European Cystic Fibrosis Society Patient Registry (Ireland) |
| Alison Cave | European Medicines Agency |
| Kelly Plueschke | European Medicines Agency |
| Mireia Castillon | European Medicines Agency |
| Carla Alonso | European Medicines Agency |
| Registry Holders | Affiliation |
| Hanne Vebert Olesen | European Cystic Fibrosis Society (Denmark) |
| Jacqueline Noordhoek | Cystic Fibrosis Europe (The Netherlands) |
| Vincent Gulmans | European Cystic Fibrosis Society (The Netherlands) |
| Lydie Lemonnier | Defeating Cystic Fibrosis (France) |
| Isabelle de Monestrol | European Cystic Fibrosis Society (Sweden) |
| Lutz Nährlich | European Cystic Fibrosis Society Patient Registry (Germany) |
| Siobhán Carr | Cystic Fibrosis Trust (UK) |
| Noreen Caine | Cystic Fibrosis Trust (UK) |
| National Authority | Affiliation |
| François Meyer | Health Technology Assessment (France) |
| Patient Representative | Affiliation |
| Name to be confirmed | |
| Member States | Affiliation |
| Concepcion Prieto Yerro | Spanish Agency of Medicinal Products and Medical Devices (Spain) |
| Robert Hemmings | Medicines and Healthcare Products Regulatory Agency (UK) |
| Melinda Sobor | National Institute of Pharmacy and Nutrition (Hungary) |

| Patient Representative | Affiliation |
|-------------------------------------|---|
| Piotr Fiedor | Office for the Registration of Medicinal Products, Medical Devices and Biocidal Products (Poland) |
| Almath Spooner | Health Products Regulatory Authority (Ireland) |
| Sabine Straus | Medicines Evaluation Board (The Netherlands) |
| Hanneke van der Woude | Medicines Evaluation Board (The Netherlands) |
| Karolina Torneke | Medical Products Agency (Sweden) |
| Maria Fernandez | Spanish Agency of Medicinal Products and Medical Devices (Spain) |
| Nithyanandan Nagercoil | Medicines and Healthcare Products Regulatory Agency (UK) |
| Valerie Joynson | Medicines and Healthcare Products Regulatory Agency (UK) |
| Carla Jonker | Medicines Evaluation Board (The Netherlands) |
| Martin Erik Nyeland | Danish Medicines Agency (Denmark) |
| Natividad Galiana | Spanish Agency of Medicinal Products and Medical Devices (Spain) |
| EMA | |
| Jane Moseley | European Medicines Agency |
| Laura Fregonese | European Medicines Agency |
| Irmgard Eichler | European Medicines Agency |
| Corinne de Vries | European Medicines Agency |
| Frank Petavy | European Medicines Agency |
| Andrea Taft | European Medicines Agency |
| Valerie Muldoon | European Medicines Agency |
| Industry | Affiliation |
| Gerhild Angyalosi | Novartis |
| Florian Gutzwiller | Novartis |
| Nils Kinnman | Vertex |
| Flaminia Macchia | Vertex |
| Claudia Meyer | Horizon Pharma |
| Saskia Dekker | Horizon Pharma |
| Anne-Ruth van Troostenburg de Bruyn | Gilead Science |